

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

Corine Ekhart · J. Martijn Kerst · Sjoerd Rodenhuis ·
Jos H. Beijnen · Alwin D. R. Huitema

Received: 22 January 2008 / Accepted: 7 April 2008
© The Author(s) 2008

Abstract

Purpose We report a patient with renal insufficiency (creatinine clearance, $CL_{cr} = 38$ mL/min) who received high-dose chemotherapy with cyclophosphamide ($1,500$ mg/m² day⁻¹), thiotepa (120 mg/m² day⁻¹) and carboplatin ($AUC = 5$ mg min/mL day⁻¹) for four consecutive days.

Methods Blood samples were collected on day 1 and 3 and plasma levels of cyclophosphamide, its active metabolite 4-hydroxycyclophosphamide, thiotepa, its main metabolite tepla and carboplatin were determined.

Results Pharmacokinetic analyses indicated that the elimination of cyclophosphamide, thiotepa, carboplatin, but especially tepla was strongly reduced in this patient, resulting in increased exposures to these compounds of 67, 43, 30 and 157%, respectively, compared to a reference population ($n = 24$) receiving similar doses. Exposure to 4-hydroxycyclophosphamide increased 11%.

Conclusion These results suggest that it may not be necessary to alter the dose of cyclophosphamide in patients with moderate renal impairment. However, because high exposures to thiotepa and tepla have been correlated with

increased toxicity, caution should be applied when administering thiotepa to patients with renal insufficiency.

Keywords Renal insufficiency · Cyclophosphamide · Thiotepa · Pharmacokinetics

Introduction

Cyclophosphamide and thiotepa are alkylating agents that belong to the most frequently used cytotoxic agents in high-dose chemotherapy regimens. A regimen that is commonly used in the Netherlands is the CTC regimen, which consists of cyclophosphamide ($6,000$ mg/m²), thiotepa (480 mg/m²) and carboplatin ($1,600$ mg/m²) divided over 4 days administered in short infusions [1].

When using chemotherapeutic agents at the limit of non-haematological toxicity, there is a substantial risk of adverse outcome. A wide interpatient variability in toxicity of cyclophosphamide, thiotepa and carboplatin has been described, which can be explained in part by the interpatient variability in pharmacokinetics of the respective compounds. Various relations between exposure and toxicity or even efficacy have been identified [2].

Cyclophosphamide is a prodrug that needs to be activated by cytochrome P450 to 4-hydroxycyclophosphamide, which is the main route of metabolism. Both the metabolites and 12–30% of unchanged parent compound are eliminated in the urine [3]. Thiotepa is rapidly metabolised by cytochrome P450 to tepla, its main and active metabolite. Thiotepa and tepla have similar alkylating properties. Less than 2% of the administered dose of thiotepa is eliminated unchanged in the urine. Renal elimination of tepla accounts for approximately 11% of the administered dose [4, 5]. Carboplatin is a platinum compound, with renal elimination

C. Ekhart (✉) · J. H. Beijnen · A. D. R. Huitema
Department of Pharmacy and Pharmacology,
The Netherlands Cancer Institute/Slotervaart Hospital,
Louwesweg 6, 1066 EC Amsterdam, The Netherlands
e-mail: corine.ekhart@slz.nl

J. M. Kerst · S. Rodenhuis
Department of Medical Oncology,
The Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, The Netherlands

J. H. Beijnen
Section of Drug Toxicology, Department of Biomedical Analysis,
Faculty of Pharmaceutical Sciences,
Utrecht University, Utrecht, The Netherlands

accounting for almost all drug elimination. In patients with normal renal function, between 60 and 70% of an administered dose is excreted in the urine within the first 24 h of administration [6].

Renal insufficiency is a factor that may complicate drug dosing. When renal function is compromised, drug and metabolites eliminated through the kidneys will remain in the body and may accumulate to toxic levels with repeated dosing. Scarce information is available about the pharmacokinetics of (high dose) cyclophosphamide and thiotepa in patients with renal insufficiency. Earlier studies have described the pharmacokinetics of cyclophosphamide in adults with renal dysfunction receiving either standard dose [7–11] or myeloablative doses of cyclophosphamide [12, 13]. However, data are controversial. Minimal effects of renal dysfunction upon cyclophosphamide AUC have been reported [8, 11, 12], while others have shown an elevated AUC in those with impaired renal function [9, 10, 13]. A report in an anephric child indicated that off haemodialysis clearance of cyclophosphamide was similar to cyclophosphamide clearance in children with normal renal function [14]. Studies reporting the impact of renal dysfunction upon the metabolites of cyclophosphamide show that plasma alkylating activity was increased in patients with renal failure [7, 10, 11].

It has been shown that carboplatin clearance is decreased in patients with decreased renal function, resulting in increased toxicity [15]. Dose adjustment of carboplatin is required in these patients. The Calvert formula is widely used for carboplatin dosing based on the glomerular filtration rate [16].

In this report we describe the pharmacokinetics of cyclophosphamide, its active metabolite 4-hydroxycyclophosphamide, thiotepa, its active metabolite tepla and carboplatin in a patient with renal insufficiency.

Patients and methods

Case

A 40-year-old male patient was diagnosed with Ewing sarcoma. As part of his treatment he received one course of high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation, consisting of cyclophosphamide ($1,500 \text{ mg/m}^2 \text{ day}^{-1}$) as 1-h infusion, immediately followed by carboplatin [dose calculated based on modified Calvert formula: $\text{AUC (mg min/mL)} = \text{Dose (mg)} / (\text{CL}_{\text{cr}} (\text{mL/min}) + 25)$ with 5 mg min/mL as daily target AUC] as 1-h infusion and thiotepa ($120 \text{ mg/m}^2 \text{ day}^{-1}$) divided over two 30-min infusions 12 h apart, for four consecutive days. Full details of the CTC regimen have been published previously [17].

The patient had normal cardiac, hepatic, haematopoietic and pulmonary function. Renal function was, however, impaired (calculated creatinine clearance 38 mL/min , using the Cockcroft–Gault equation [18]).

Pharmacokinetic analysis

For pharmacokinetic analyses, blood samples were collected from a double lumen intravenous catheter inserted in a subclavian vein. Samples were collected on day 1 and 3 prior to the start of the infusions, at 30 min after the start of cyclophosphamide infusion ($t = 30$) and $t = 60$ (end of cyclophosphamide infusion), 90, 120 (end of carboplatin infusion), 150 (end of thiotepa infusion), 180, 210, 285, 390 and 660 min. Samples were processed as described previously [19–21]. Analytical methods used for the determination of plasma concentrations of cyclophosphamide, 4-hydroxycyclophosphamide, thiotepa, tepla and carboplatin have been reported previously [19–21].

Population pharmacokinetic models of carboplatin, cyclophosphamide (and its metabolite 4-hydroxycyclophosphamide) and thiotepa (and its metabolite tepla) were used for calculating the pharmacokinetic parameters of all compounds using Bayesian analysis [2, 22]. The pharmacokinetic parameters of the different compounds in this patient were compared with the respective median values in a reference population of patients ($n = 24$) who also received CTC and were dosed (except for carboplatin, reference population received $400 \text{ mg/m}^2 \text{ day}^{-1}$) and sampled as described above. Complete pharmacokinetic profiles of the reference population were available of day 1 and day 3 or 4. Exposure was defined as the cumulative exposure of the 4-day course extrapolated to infinity. The protocol was approved by the Committee on the Medical Ethics of the Netherlands Cancer Institute and written informed consent was obtained from the patient.

Results

Administration of cyclophosphamide, thiotepa and carboplatin in this patient led to increased exposures to all compounds. Table 1 shows the median cumulative exposures following one course in both the population and the patient, the latter based on the pharmacokinetics obtained on the first day of the 4-day course. Figure 1 shows the plasma concentration–time data of the patient versus the typical plasma concentration–time curve of the reference population [2, 22].


Comparing pharmacokinetic parameters of cyclophosphamide, thiotepa and carboplatin in this patient with those in the reference population, it appeared that the renal clearance of cyclophosphamide and thiotepa decreased

Table 1 Overall exposure (expressed as AUC) to the different compounds and their metabolites during the course, if no dose adjustment would have been done

Compound	AUC units	AUC patient	Median AUC reference population	2.5–97.5% range	Deviation (%)
Cyclophosphamide	uM h	11,467	6,871	4,355–10,664	67
4-Hydroxycyclophosphamide	uM h	157	142	105–186	11
Thiotepa	uM h	185	129	81–201	43
Tepa	uM h	648	252	108–427	157
Thiotepa and tepa	uM h	833	384	222–584	117
Carboplatin	mg min/mL	26	20 ^a		30

^a Target AUC value, reference population received carboplatin dose of 400 mg/m² day⁻¹

Fig. 1 Concentration–time curves of **a** cyclophosphamide (CP), **b** 4-hydroxycyclophosphamide (4OHCP), **c** thiotepa (TT), **d** tepa (T) and **e** carboplatin (CA) with *triangle* representing the patient and *filled square* the typical plasma concentration–time curve of the reference population



in the patient compared to the reference population with 28 and 36%, respectively (2.1 vs. 2.9 L/h and 15.9 vs. 24.9 L/h). This resulted in an increased exposure to cyclophosphamide and thiotepa of 67 and 43%, respectively. Exposure to 4-hydroxycyclophosphamide was only moderately increased, due to a minor decrease in elimination of 4-hydroxycyclophosphamide (7%) and a minor increase in metabolic fraction (11%), compared to the reference population. Exposure to tepa, however, increased dramatically (157%), mainly due to a decreased elimination rate constant of tepa (0.23 h⁻¹ in the patient vs. 0.47 h⁻¹ in the reference

population). Although carboplatin was dosed based on creatinine clearance the exposure was still 30% above the target value (26 vs. 20 mg min/mL).

Based on the pharmacokinetic analyses of day 1 of the course, the doses of cyclophosphamide, thiotepa and carboplatin were reduced on days 3 and 4 to reach a predefined target exposure (the median exposure in a reference population receiving similar doses) [23]. The cyclophosphamide dose was reduced from 2,955 to 2,550 mg/day, the thiotepa dose from 236 to 162 mg/day and the carboplatin dose from 315 to 275 mg/day. This resulted in an exposure closer to

the target exposure. Combined exposure to thiotepa and tepla, however, was still 75% above the target. Renal function remained the same during the 4 days of chemotherapy.

The patient experienced grade 3 mucositis and diarrhoea. Furthermore, grade 2 aspartate aminotransferase (ASAT) and bilirubin toxicity was observed. In the reference population three patients experienced grade 3 mucositis (12.5%), no patients had grade 3 diarrhoea, six patients experienced grade 2 ASAT toxicity (25%) and one patient had grade 2 bilirubin toxicity (4.2%). On day 43 post-transplantation the patient died due to acute respiratory distress syndrome.

Discussion

Renal insufficiency alters the pharmacokinetics of drugs. If drugs or their active metabolites are excreted by the kidneys they can accumulate in patients with renal insufficiency. In the patient reported here, increased exposures to cyclophosphamide, 4-hydroxycyclophosphamide, thiotepa, tepla and carboplatin were observed.

The patient described here experienced excessive exposure to tepla. Renal elimination of thiotepa accounts for only a small part of its elimination, for tepla, apparently, renal elimination is an important route. Toxicities associated with thiotepa treatment are mainly mucositis and central nervous system toxicity. The most frequently affected organs being the liver and gastrointestinal tract, resulting in nausea, vomiting and diarrhoea [4]. Moreover, a relation between ASAT toxicity and thiotepa AUC has been demonstrated [2]. Indeed, this patient experienced severe mucositis and diarrhoea and grade 2 ASAT toxicity, probably due to excessive exposure to thiotepa and tepla.

Clearance of cyclophosphamide was reduced, which resulted in an increase in cyclophosphamide exposure. Since cyclophosphamide itself is not active, increases in exposure to the active metabolites are more important for the interpretation of the clinical relevance of this effect. The exposure to 4-hydroxycyclophosphamide was only moderately increased, indicating no need to adjust the dose of cyclophosphamide in patients with moderate renal insufficiency. Our data are in agreement with the data of Juma et al. [10] who reported a lower clearance (−17%) and an increase in half-life (+24%) of cyclophosphamide in five patients with moderate to severe renal insufficiency (creatinine clearances 18–51 mL/min) compared to eight matched controls with normal renal function. Similar results were reported by Haubitz et al. [9] who found a lower clearance (−28%) of cyclophosphamide in patients with creatinine clearances of 25–50 mL/min, which resulted in an increase in systemic drug exposure of 38%. Mouridsen et al. [11] showed that the biotransformation rate is unaffected in

patients with renal impairment. Bramwell et al. [8] could not demonstrate a correlation between renal function and clearance of cyclophosphamide or its alkylating metabolites due to the large inter-individual variability in cyclophosphamide break-down seen in that study. Further data regarding the impact of renal dysfunction upon the metabolites of cyclophosphamide are scarce. One study showed that total alkylating activity as measured by the nitrobenzylpyridine (NBP) reaction was significantly increased in renal failure [10]. However, this NBP reaction is highly non-specific and variable [24]. Therefore, no firm conclusions could be attributed to this result. A report about cyclophosphamide disposition in an anephric child showed that the exposure to 4-hydroxycyclophosphamide off haemodialysis was in the same range as our results [14]. Clinically relevant changes in cyclophosphamide pharmacology due to alterations in renal function have not been demonstrated.

For carboplatin it is known that renal insufficiency causes increased exposure to carboplatin. Therefore, a priori dose adjustments of carboplatin are performed. Although this patient had an adjusted dose of carboplatin based on his creatinine clearance, exposure to carboplatin was still 30% above the target exposure. Substitution of the glomerular filtration rate in the Calvert formula by an estimate of creatinine clearance calculated using the Cockcroft–Gault equation led to an overestimation of the carboplatin clearance in this patient. Froissart et al. [25] showed that the use of the Cockcroft–Gault equation can lead to overestimation of the glomerular filtration rate in patients with GFR <60 mL/min.

In conclusion, this case report demonstrates the pharmacokinetic disposition of cyclophosphamide, 4-hydroxycyclophosphamide, thiotepa, tepla and carboplatin in a patient with reduced renal function. Renal insufficiency in this patient resulted in a high exposure to thiotepa and especially tepla and is, therefore, of potential clinical importance. Additional pharmacokinetic and pharmacodynamic data are warranted in future studies to provide more accurate dosage recommendations for thiotepa in these patients.

Acknowledgment This work was supported with a grant from the Dutch Cancer Society (project NKI 2005-3418).

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Rodenhuis S, Richel DJ, van der WE, Schornagel JH, Baars JW, Koning CC et al (1998) Randomised trial of high-dose chemo-

- therapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. *Lancet* 352(9127):515–521
2. Huitema ADR, Spaander M, Mathot RAA, Tibben MM, Holtkamp MJ, Beijnen JH et al (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. *Ann Oncol* 13(3):374–384
 3. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. *Clin Pharmacokinet* 44(11):1135–1164
 4. van Maanen MJ, Smeets CJ, Beijnen JH (2000) Chemistry, pharmacology and pharmacokinetics of N, N', N''-triethylenethiophosphoramidate (ThioTEPA). *Cancer Treat Rev* 26(4):257–268
 5. Huitema ADR, Smits KD, Mathot RA, Schellens JH, Rodenhuis S, Beijnen JH (2000) The clinical pharmacology of alkylating agents in high-dose chemotherapy. *Anticancer Drugs* 11(7):515–533
 6. van der Vijgh WJ (1991) Clinical pharmacokinetics of carboplatin. *Clin Pharmacokinet* 21(4):242–261
 7. Bagley CM Jr, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. *Cancer Res* 1973; 33(2):226–233
 8. Bramwell V, Calvert RT, Edwards G, Scarffe H, Crowther D (1979) The disposition of cyclophosphamide in a group of myeloma patients. *Cancer Chemother Pharmacol* 3(4):253–259
 9. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. *Kidney Int* 61(4):1495–1501
 10. Juma FD, Rogers HJ, Trounce JR (1981) Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. *Eur J Clin Pharmacol* 19(6):443–451
 11. Mouridsen HT, Jacobsen E (1975) Pharmacokinetics of cyclophosphamide in renal failure. *Acta Pharmacol Toxicol (Copenh)* 36(Suppl 5):409–414
 12. Bischoff ME, Blau W, Wagner T, Wagenmann W, Dorner O, Basara N et al (1998) Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. *Bone Marrow Transplant* 22(6):591–593
 13. Perry JJ, Fleming RA, Rocco MV, Petros WP, Bleyer AJ, Radford JE Jr et al (1999) Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. *Bone Marrow Transplant* 23(8):839–842
 14. McCune JS, Adams D, Homans AC, Guillot A, Iacono L, Stewart CF (2006) Cyclophosphamide disposition in an anephric child. *Pediatr Blood Cancer* 46(1):99–104
 15. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW et al (1984) Pharmacokinetics and dosage reduction of cis-diammine(1, 1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. *Cancer Res* 44(11):5432–5438
 16. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 7(11):1748–1756
 17. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. *N Engl J Med* 349(1):7–16
 18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. *Nephron* 16(1):31–41
 19. Ekhardt C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, Huitema ADR (2007) Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). *J Chromatogr B Analyt Technol Biomed Life Sci* 854(1–2):345–349
 20. Huitema ADR, Tibben MM, Kerbusch T, Zwikker JW, Rodenhuis S, Beijnen JH (1998) Simultaneous determination of N, N', N''-triethylenethiophosphoramidate, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. *J Chromatogr B Biomed Sci Appl* 716(1–2):177–186
 21. Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen J (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. *Fresenius' journal of analytical chemistry* 351:777–781
 22. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2004) Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. *J Pharmacokinet Pharmacodyn* 31(2):135–156
 23. de Jonge ME, Huitema ADR, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH (2005) Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. *Clin Cancer Res* 11(1):273–283
 24. Lewis LD (1991) Ifosfamide pharmacokinetics. *Invest New Drugs* 9(4):305–311
 25. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P (2005) Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. *J Am Soc Nephrol* 16(3):763–773